{"nctId":"NCT00690820","briefTitle":"Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)","startDateStruct":{"date":"2008-06"},"conditions":["Cystic Fibrosis","Pancreatic Exocrine Insufficiency"],"count":17,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Pancrelipase Delayed Release"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Comparator"]}],"interventions":[{"name":"Pancrelipase Delayed Release","otherNames":[]},{"name":"Placebo Comparator","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis\n* Confirmed PEI by historical Coefficient of fat Absorption \\< 70% without supplementation or current or historical fecal elastase \\< 50µg/stool (within the last 12 months)\n* Currently receiving treatment with a commercially available pancreatic enzyme product on a stable dose for more than 3 months\n* Clinically stable condition without evidence of acute respiratory disease or any other acute condition\n* Stable body weight and agrees to abstain from sexual activity\n\nExclusion Criteria:\n\n* Ileus or acute abdomen\n* History of fibrosing colonopathy, celiac disease, gastrectomy, Crohn´s disease and small bowel surgery other than minor resection due to meconium ileus without resulting in malabsorption syndrome\n* History of distal ileal obstruction syndrome within 6 months of enrollment\n* Use of an immunosuppressive drug\n* Any type of malignancy involving the digestive tract in the last 5 years\n* Known infection with HIV","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Coefficient of Fat Absorption (%)","description":"This coefficient is calculated from fat intake and fat excretion : 100\\*\\[fat intake-fat excretion\\]/fat intake. Stools were collected on 3 days during the 5 days treatment period. Higher values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.41","spread":"16.84"},{"groupId":"OG001","value":"82.81","spread":"8.29"}]}]}]},{"type":"SECONDARY","title":"Coefficient of Nitrogen Absorption (%)","description":"This coefficient is calculated from nitrogen intake and nitrogen excretion : 100\\*\\[nitrogen intake-nitrogen excretion\\]/nitrogen intake. Stools were collected on 3 days during the 5 days treatment period. Higher values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.98","spread":"20.47"},{"groupId":"OG001","value":"80.33","spread":"7.92"}]}]}]},{"type":"SECONDARY","title":"Total Fat Excretion (Grams)","description":"Total amount of fat excreted during the stool collection period. Stools were collected on 3 days during the 5 days treatment period. Lower values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.9","spread":"68.0"},{"groupId":"OG001","value":"58.1","spread":"27.5"}]}]}]},{"type":"SECONDARY","title":"Total Stool Weight (Grams)","description":"Total weight of the stools collected during the stool collection period. Stools were collected on 3 days during the 5 days treatment period. Lower values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"436.5","spread":"158.4"},{"groupId":"OG001","value":"161.4","spread":"57.5"}]}]}]},{"type":"SECONDARY","title":"Stool Frequency","description":"Stool frequency is the average of the daily number of stools recorded during the treatment period. Lower values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":"1.06"},{"groupId":"OG001","value":"1.88","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With no Flatulence.","description":"The percentage of days with no flatulence is calculated from the diary during the treatment period: 100\\*(number of days with no flatulence/number of days recorded in diary). Higher values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":"36.9"},{"groupId":"OG001","value":"45.0","spread":"42.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With Formed/Normal Stools.","description":"The percentage of days with formed/normal stools is calculated from the diary during the treatment period: 100\\*(number of days with formed/normal stools/number of days with any stool). Higher values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":"33.0"},{"groupId":"OG001","value":"77.7","spread":"27.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With no Abdominal Pain.","description":"The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100\\*(number of days with no abdominal pain / number of days recorded in diary). Higher values indicate a better response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":"28.9"},{"groupId":"OG001","value":"85.3","spread":"21.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Abdominal Pain","Diarrhoea","Flatulence","Vomiting","Blood glucose increased"]}}}